Crohn's Disease
SEQUENCE: Skyrizi outperforms for Crohn’s remission; Stelara ‘still remains on the table’
WASHINGTON — Although a greater number of patients with Crohn’s disease who failed anti-TNF therapy achieved biologic remission with Skyrizi vs. Stelara, choosing between the two therapies “still remains on the table,” a researcher noted.
Statin use linked to ‘sharp 86% risk reduction’ for primary sclerosing cholangitis in IBD
WASHINGTON — Statin use was associated with up to a 90% risk reduction for new-onset primary sclerosing cholangitis among patients with inflammatory bowel disease, according to data presented at Digestive Disease Week.
Low anti-TNF concentrations at week 14 linked to long-term loss of response in Crohn’s
Approximately two-thirds of patients with Crohn’s disease who initially responded to anti-tumor necrosis factor therapy lost response by 3 years, with researchers suggesting that higher drug concentrations at induction may improve outcomes.
FDA warns of ‘rare risk’ for thiopurine-related intrahepatic cholestasis of pregnancy
The FDA has issued a safety alert warning patients and health care providers of a “rare risk of intrahepatic cholestasis of pregnancy” linked to thiopurine use.
FDA approves high-concentration, citrate-free form of interchangeable biosimilar Cyltezo
The FDA has approved a citrate-free, high-concentration formulation of the interchangeable adalimumab biosimilar Cyltezo to treat multiple chronic inflammatory diseases, according to the manufacturer.
Family planning in IBD: ‘It is our responsibility’ to share accurate resources, support
A young woman, newly diagnosed with inflammatory bowel disease, sits in your office.
Takeda’s Entyvio snags second FDA approval as ‘subcutaneous option’ for Crohn’s disease
The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in adult patients with moderate-to-severe Crohn’s disease following induction therapy via IV administration of the biologic.
Benefit of biosimilar switching ‘less apparent’ to GIs, patients vs. third-party payers
If you see more than a few patients with inflammatory bowel disease, you likely already have been asked by a third-party payer to switch a patient’s adalimumab prescription from the reference product to a biosimilar.
Interchangeable biosimilars may cut costs or cause ‘cognitive dissonance’
The age of biosimilars has come for gastroenterology. This includes interchangeable products, three of which are now on the market. How this will impact patient care in the near and distant future is the subject of much speculation.
Amjevita leads Humira biosimilars in clinician comfort as rheumatologists remain wary
Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for all other adalimumab biosimilars combined, according to a market analysis from Spherix Global Insights.